Clinical trials: Mental Disorder
Alzheimer's Disease
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease
This is a prospective, 26-week, open-label, single-arm multi-center pilot study. Eligible patients will receive open-label treatment with rivastigmine capsules plus memantine tablets as add on therapy.
- Trial name
- NCT00305903
- Testing
- Rivastigmine, memantine
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Novartis
Attention Deficit Hyperactivity Disorder
Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)
The study is long-term extension study to evaluate long-term safety and efficacy of Atomoxetine in Japanese pediatric patients with Attention-Deficit/Hyperactivity Disorder (AD/HD).
- Trial name
- NCT00191386
- Testing
- Atomoxetine hydrochloride
- Where
- 24 sites in Japan
- Volunteers
- 228 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder
GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers
This is a First Time in Human Study to assess the safety, tolerability, pharmacokinetics and resting motor threshold (rMT) of single doses of GSK drug in healthy volunteers.This will be a 2 part and 2 centre study.Part 1 will be…
- Trial name
- NCT00488566
- Testing
- GSK drug, Lamictal
- Where
- 2 sites in United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Biogen
Erectile Dysfunction
The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fed Versus 100 mg of Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fasted Conditions in Healthy Adult Male Subjects
The objective of this phase 1 study is to evaluate the food effect of 100 mg Hezkue Turbo® (ASP-001.1, sildenafil) under fed versus 100 mg of Hezkue Turbo® (ASP-001.1, sildenafil) under fasted conditions in healthy adult male…
- Trial name
- NCT06872866
- Testing
- ASP-001.1
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Aspargo Labs, Inc
Major Depressive Disorder
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
The primary purpose of this study is to compare the long-term efficacy and safety of desvenlafaxine succinate sustained release versus placebo in adults with Major Depressive Disorder, using a randomized withdrawal design.
- Trial name
- NCT00887224
- Testing
- Desvenlafaxine succinate sustained release 50 mg, Desvenlafaxine succinate sustained release 25 mg
- Where
- 90 sites in United States, Canada and 12 more
- Volunteers
- 874 people
- Sponsor
- Pfizer
Schizophrenia
Zyprexa® Relprevv™ Patient Care Program
The goal of the Zyprexa Relprevv Patient Care Program is to mitigate the risk of negative outcomes associated with Zyprexa Relprevv post-injection delirium/sedation syndrome (PDSS).
- Trial name
- NCT01088386
- Where
- United States
- Volunteers
- 4,000 people
- Sponsor
- Eli Lilly and Company
Sleep Disorders, Obstructive Sleep Apnea
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
The primary objective of the study is to evaluate whether armodafinil at a target dosage of 200 mg/day is more effective than placebo treatment in improving excessive sleepiness in patients with obstructive sleep apnea/hypopnea…
- Conditions
- Sleep Disorders, Obstructive Sleep Apnea, Major Depressive Disorder, Dysthymic Disorder
- Trial name
- NCT00518986
- Testing
- armodafinil
- Where
- 62 sites in United States
- Volunteers
- 249 people
- Sponsor
- Cephalon
Major Depressive Disorder
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Trial name
- NCT06786624
- Testing
- NBI-1065845
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Neurocrine Biosciences
Insomnia, Insomnia (Moderate)
ASV Therapy for Insomnia
This will be a single center, prospective study designed to evaluate the effect of adaptive servo ventilation therapy on insomnia severity among patients with moderate to severe chronic insomnia.
- Trial name
- NCT07011966
- Testing
- ASV therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- ResMed
Bipolar Disorder
3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
Bipolar disorder is characterized by mood swings that range from high (manic) to low (depressed) states. Sometimes, symptoms of both depression and mania are present (mixed episodes).
- Trial name
- NCT00159796
- Testing
- Asenapine, Olanzapine
- Volunteers
- 489 people
- Sponsor
- Organon and Co
Impotence
Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied
Men's quality of life (QoL) is potentially affected by mild erectile dysfunction (ED) to the same extent as it is by moderate and severe ED.
- Trial name
- NCT00301262
- Testing
- Viagra (Sildenafil citrate)
- Where
- 26 sites in Canada
- Volunteers
- 183 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Social Phobia
Treatment Of Patients With Social Anxiety Disorder
GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.
- Trial name
- NCT00397722
- Testing
- GW876008, paroxetine
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 299 people
- Sponsor
- GlaxoSmithKline
Narcolepsy
A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy
The rationale for the patient-centric, prospective, observational, non-interventional study design of JZP258-402 is to evaluate the transition experience of participants with narcolepsy treated with oxybate and to examine the…
- Trial name
- NCT04803786
- Testing
- Transition from Xyrem to Xywav
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Jazz Pharmaceuticals
Depressive Disorder
MDD POC Study GSK372475 Subjects Depressive Disease
To evaluate the efficacy, safety and tolerability of GSK372475 compared with placebo in the treatment of outpatients subjects with major depressive disorder to exhibit decreased pleasure, interest and energy.
- Trial name
- NCT00420641
- Testing
- GSK372475, Paroxetine
- Where
- 33 sites in Bulgaria, Canada and 8 more
- Volunteers
- 492 people
- Sponsor
- GlaxoSmithKline
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB)
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily…
- Conditions
- Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD)
- Trial name
- NCT07240805
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioSensics
Autism Spectrum Disorder (ASD), Autism
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
The purpose of this study is to evaluate the safety and tolerability of memantine in pediatric (6-12 years old) patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and…
- Conditions
- Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder
- Trial name
- NCT01592786
- Testing
- Memantine Hydrochloride (HCl)
- Where
- 118 sites in United States, Australia and 16 more
- Volunteers
- 906 people
- Sponsor
- Forest Laboratories
Attention Deficit Disorder With Hyperactivity
Software Treatment for Actively Reducing Severity of ADHD
The purpose of this study is to evaluate the effects of videogame-like digital therapies on attentional functioning and symptoms in children diagnosed with ADHD.
- Trial name
- STARS-ADHD (NCT02674633)
- Testing
- AKL-T01, AKL-T09
- Where
- 20 sites in United States
- Volunteers
- 348 people
- Sponsor
- Akili Interactive Labs, Inc.
Mild Cognitive Impairment and Dementia
UK Validation of the Automated "AcceXible" Speech Analysis Software
Dementia, especially dementia caused by Alzheimer's disease, is considered one of the most severe health problems of our time. It is currently known that the disease begins many years before clinical symptoms appear.
- Trial name
- NCT05534958
- Testing
- Accexible
- Where
- United Kingdom
- Volunteers
- 221 people
- Sponsor
- Accexible
Erectile Dysfunction
Autologous Bone Marrow Concentrate in Treatment of Erectile Dysfunction.
This study assessed the safety and efficacy of autologous bone marrow concentrate and injected intra-cavernously into patients with erectile dysfunction (ED).
- Trial name
- NCT03699943
- Testing
- CaverStem
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Creative Medical Health, Inc.
Attention Deficit Hyperactivity Disorder
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
This study will evaluate atomoxetine's efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and atomoxetine's effect on functional outcomes in young adults.
- Trial name
- NCT00510276
- Testing
- Atomoxetine hydrochloride
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 445 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.